노준호 교수

<h3>Introduction/Background</h3> Theoretically, PARP inhibitors can function as a DNA damaging agents in BRCA wild type cancer, even if the clinical activity is limited. Most of epithelial ovarian cancer is characterized by TP53 mutation causing dysfunction in the G1/S checkpoint, which makes tumor cells highly dependent on Chk1-mediated G/M phase cell cycle arrest for DNA repair. Therefore, we hypothesized that combination treatment of PARP inhibitors (Rucaparib) and Chk1 inhibitor (LY2606368)

<h3>Introduction/Background</h3> To evaluate the effectiveness of closed suction technique (CST) for surgical treatment of huge ovarian cyst in terms of oncologic safety. <h3>Methodology</h3> A total of 211 women who underwent surgery including at least unilateral salpingo-oophorectomy for huge ovarian cyst ≥10 cm were retrospectively reviewed (figure 1). Information about tumor characteristics, surgical approach, gross tumor spillage during surgery (no rupture, gross rupture, and CST), patholog

<h3>Introduction/Background</h3> Prognostic factors of BRCA1/2 mutation in epithelial ovarian cancer remain controversial. We retrospectively analyzed prognostic factor of patients with ovarian cancer who underwent BRCA testing at our institute. <h3>Methodology</h3> Eighty seven patients who underwent a staging operation for pathologically proven epithelial cancer between February 2006 and August 2017 were enrolled retrospectively. The peripheral germline samples were obtained for BRCA1/2 mutati

<h3>Introduction/Background</h3> Cervical intraepithelial neoplasia (CIN) 2 in women younger than 24, observation is preferred in current treatment guidelines. In this study we evaluate the effectiveness of conservative management of CIN2 in Korean young women and find appropriate strategy considering age. <h3>Methodology</h3> A total of 129 women ≤30 years diagnosed CIN2 on punch biopsy was retrospectively reviewed. Patient characteristics, initial and follow-up results of cervical examinations

<h3>Introduction/Background</h3> Current treatment guidelines don’t mention how many cycles of chemotherapy are needed for appropriate tumor remission. This study was performed to evaluate the efficacy of additional cycles of chemotherapy in cervical cancer patients with tumor response of stable disease (SD) after six cycles. <h3>Methodology</h3> A total of 12 women who showed tumor response of SD with tumor ≥5 mm after six cycles of chemotherapy for the treatment of cervical cancer were reviewe